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Serotonin-immunoreactive axons in somatosensory cortex.
Left panel: control monkey. Right panel: monkey given subcutaneous
5 mg/kg dexfenfluramine twice daily for four days two weeks previously.
abnormalities were not seen in controls. Two weeks after
treatment, there was a striking reduction in density of 5-HT
axons in the cerebral cortex of dexfenfluramine-treated
monkeys (figure); 5-HT axons with abnormal features were
uncommon.
Our results indicate that at the doses studied
dexfenfluramine is toxic to 5-HT neurons in the brain of
non-human primates. Furthermore, dexfenfluramine
neurotoxicity is dose-related and more severe in primates
than in rodents. Since the 1 25 mg/kg dose is only about five
times that typically prescribed to patients (0-2 to 0-3
mg/kg),’ we believe that caution is necessary in the clinical
use of dexfenfluramine because, in man, it might have a
narrow margin of safety. However, in our study,
dexfenfluramine was given subcutaneously (in man the drug
is taken orally) and there may be differences in the
distribution, metabolism, or elimination of dexfenfluramine
in primates compared with man.
Despite these uncertainties, there are several reasons why
our findings might be relevant to the clinical use of
dexfenfluramine. Firstly, since the oral to parenteral ratio
for fenfluramine8 and related neurotoxic amphetamines7
approaches unity, an oral route of administration is unlikely
to give substantial protection against neurotoxicity.
Secondly, although doses of dexfenfluramine used in our
study are several-fold higher than doses typically prescribed
to patients, man could be more sensitive than animals to the
effects of this drug. Thirdly, there is great individual
variability in the pharmacokinetics of dexfenfluramine in
man;9 a safe dose in one patient could be neurotoxic in
another. Fourthly, in our study, animals received
dexfenfluramine for only four days, whereas patients usually
receive the drug for twelve weeks, and sometimes for a year. 1
Finally, since the half-life of dexfenfluramine is much longer
in man (17-8 h) than in rodents (2-5 h),69 there is greater risk
in humans that chronic dosing will produce toxic drug
concentrations.
If dexfenfluramine produces 5-HT neurotoxicity in man,
what might the clinical consequences be? Although the
function of 5-HT in human brain has yet to be fully defined,
clinical evidence suggests that 5-HT loss may lead to
disturbances of mood, sleep, impulse control, sexual
activity, and neuroendocrine function.1O These changes in
5-HT function may be subtle and difficult to detect.
Systematic studies of 5-HT function in man are needed, and
the possibility that dexfenfluramine (especially at high
doses) might be toxic to 5-HT neurons in the human brain
needs to be investigated.
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First-pass metabolism of
cyclosporin by the gut
Cyclosporin is thought to be exclusively
metabolised in the liver. We instilled cyclosporin into
the small bowel of 2 patients during the anhepatic
phase of liver transplantation; cyclosporin
metabolites were readily detected in portal venous
blood. Our findings indicate that the small intestine is
a major site of cyclosporin breakdown: such
intestinal metabolism might help to explain the poor
oral bioavailability and drug interactions of
cyclosporin.
Administration of cyclosporin, a potent immuno-
suppressant used to prevent transplanted organ rejection,
is complicated by its poor and unpredictable oral
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HPLC trace of portal vein blood (patient A) before and 60 min
after duodenal instillation of cyclosporin during anhepatic
phase of liver transplantation.
bioavailability.1,2 Cyclosporin is widely assumed to be
metabolised exclusively in the liver, but the principal
enzyme (cytochrome P450IIIA) that produces the three
major cyclosporin metabolites (Ml, M17, and M21) in liver3
is also found in enterocytes.4 Could first-pass metabolism of
cyclosporin in the gut account in part for its poor oral
bioavailability? To test this hypothesis, we instilled
cyclosporin into the small bowel of 2 patients during the
anhepatic phase of liver transplantation and measured
cyclosporin metabolites in portal blood.
2 patients with chronic cryptogenic cirrhosis who had not
previously received cyclosporin agreed to the study, which was
approved by the committee for the conduct of human research at the
University of Michigan Medical School. Routine venovenous
bypass was established during the anhepatic phase of orthotopic
liver transplantation, and portal blood, with blood from the femoral
vein, was diverted to the axillary vein with the assistance of a
centrifugal pump (average flow rate 3 1/min). An enteric feeding
tube was passed transnasally to the distal duodenum, through which
2 mg/kg cyclosporin (’Sandimmune’ oral solution, Sandoz, East
Hanover, New Jersey, USA) was given, flushed with 30 ml normal
saline, and gently massaged into the proximal jejunum by the
surgeon. In the first patient (A), 12 ml bile was aspirated from the
gallbladder and given with cyclosporin to facilitate its absorption.
5 ml blood samples were obtained simultaneously from the portal
vein cannula and from an indwelling catheter in the femoral artery
immediately before cyclosporin administration. Samples were then
drawn at intervals during the anhepatic phase, and stored with
edetic acid at 4&deg;C, the final samples were obtained just before the
transplanted liver was reperfused. After solid-phase extraction,
samples were analysed by high-performance liquid
chromatography (HPLC), as previously described,s with purified
Ml, M17, M18, and M21 metabolites used as standards; this
technique accurately measures cyclosporin and metabolite
concentrations of and above 5 ng/mi .5
CYCLOSPORIN AND METABOLITE (Ml AND M21)
CONCENTRATIONS IN PORTAL VEIN (PV) AND FEMORAL
ARTERY (FA) AFTER DUODENAL INSTILLATION DURING
ANHEPATIC PHASE
Cyclosporin was absorbed from the intestinal lumen
during the anhepatic phase of liver transplantation and
detected by 30 min in patient A (see figure) and by 40 min in
patient B (see table). The low cyclosporin concentrations in
blood from patient B probably reflect an absence of bile,
which facilitates cyclosporin absorption from the gut
lumen.1 Ml and M21 were also readily identified in both
patients; towards the end of the anhepatic phase these
metabolites represented 25 % and 51 %, respectively, of total
identifiable cyclosporin in portal blood (table). M17 could
not be measured accurately by HPLC because a
confounding peak in this region (see figure) was found in
baseline samples from both patients.
Our findings show unequivocal and striking extrahepatic
metabolism of cyclosporin. This metabolism almost
certainly took place in the small intestine. At the end of the
anhepatic phase, concentrations of cyclosporin metabolites
were higher in portal vein samples than in blood from the
femoral artery. Moreover there is little evidence of
cytochrome P450IIIA (which metabolises cyclosporin to
Ml, M17, and M21) in tissues other than t] i liver or gut,
and studies in rats have shown that P450III: enzymes in
enterocytes do metabolise cyclosporin.7
Our data probably underestimate total intestinal
cyclosporin metabolism in both patients studied: P450IIIA
also produces the M17 metabolite of cyclosporin,3,6 which
could not be measured accurately because of a baseline
HPLC peak in this region. It is also likely that other HPLC
peaks, such as that at 24-5 min (X on figure), also represent a
cyclosporin metabolite. The gut’s contribution to
cyclosporin metabolism might therefore rival or even exceed
that of the liver.
Several drug interactions of cyclosporin are consistent
with substantial cyclosporin metabolism by P450IIIA in
enterocytes. Cotreatment with oral erythromycin, a known
inhibitor of P450IIIA,8 leads to a striking increase in
maximum and area-under-the-curve (AUC) blood
concentrations of cyclosporin-changes which are not
observed when erythromycin is given intravenously;9
inhibition of enterocyte P450IIIA by erythromycin might
allow more non-metabolised cyclosporin to be absorbed.
We have also described a liver transplant recipient who had
low hepatic P450IIIA activity as measured by the [1’C]-
erythromycin breath test:lO treatment with rifampicin to
induce his donor liver P450IIIA led to a normal [14C]-
erythromycin breath test result, but effectively abolished
oral bioavailability of cyclosporin. The suggestion that
induction of enterocyte P450IIIA by rifampicin accounted
for the fall in the oral bioavailability of cyclosporin 10 is
supported by our finding of substantial cyclosporin
metabolism in the small intestine. Enterocyte metabolism
may partly account for the poor oral availability of
cyclosporin and the effects of drugs and diet on cyclosporin
absorption. The small intestine is rarely thought of as an
important site of drug metabolism, but our observations for
cyclosporin might also be relevant to the poor oral
bioavailability of other substrates of cytochrome P450IIIA,
including erythromycin, lignocaine, and oestrogens.
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p53 germline mutations in
Li-Fraumeni syndrome
Germline mutations within a defined region of the
p53 gene have recently been found in families with
the Li-Fraumeni syndrome (LFS). In the present
study this region of p53 was sequenced in affected
individuals from 8 families with LFS. In only 2 of
them were such mutations detected. Our findings
suggest that the p53 mutation could be the primary
lesion in some but not all families with LFS, and
confirm that there is a "hot spot" for these mutations
at the CpG dinucleotide moiety of codon 248.
Assigning risks and counselling families on the basis
of presence of p53 mutations should be approached
with caution.
The principal features of the Li-Fraumeni syndrome
(LFS) include sarcomas in children and young adults and
premenopausal breast cancer in their close relatives.’ 1
Germline mutations within a defined region of the p53 gene
have recently been found in affected members and obligate
carriers in families with LFS.2,3 These mutations were
located in a stretch of 25 codons evolutionarily conserved.2
In sporadic tumours, this region of the gene often contains a
INDIVIDUALS TESTED FROM EACH FAMILY
ALL= acute lymphoblastic leukaemia, Mut248=mutation at codon 248 (full
pedigrees of families tested are available from J M B Wt = wild type
*Both patients
mutation.4 The aim of our study was to see how common
these mutations might be in such families.
Families were eligible for the study if they fulfilled the criteria
defmed by Li et al. Blood samples were taken from at least 1
affected member of 8 such families. DNA was extracted from blood
or lymphoblastoid cell lines and from paraffin-embedded tissue.6,7
The conserved region in the 7th exon of p53 was amplified with the
oligonucleotides GTTGTCTCCTAGGTGGCTC and
TGGCAAGTGGCTCCTGACCT. Amplification was done in
the presence of 1 ’5 /lffioljl MgClz, 50 /lffiolfl of each dNTP, and 1
umol/1 of each oligonucleotide for 30 to 35 cycles (94&deg;C, 1 min;
58&deg;C, 1 min; and 74&deg;C, 1 min): the first cycle was preceded by a step
at 95&deg;C for 5 min after which 2 units of Taq polymerase were added.
The final elongation step was extended by 5 min.
The amplified product was phosphorylated with T4-
polynucleotidekinase and ATP, filled in by means of Klenow
enzyme (DNA polymerase 1, large fragment) and dNTP, ligated to
SmaI-cut dephosphoryiated M13mpll (Amersham, UK), and
cloned into Escherichia coli (strain XL1 Blue, Stratagene, La Jolla,
USA) by standard methods. For at least 1 individual of each family
a minimum of eight clones from at least two independent
amplifications were sequenced with the ’Multiwell Sequencing
System’ (Amersham). Direct sequencing’! was done to confirm the
presence of mutations in other affected members of the families in
which mutations were found. For family 8, material from 16
members (affected and unaffected) was available and a
polymorphism in exon 4 of p53 was analysed.9 This polymorphism
was detected by amplification with the pair of oligonucleotides
CCCGGACGATATTGAACAATGGT and CCAGA-
CGGAAACCGTAGCTGC before digestion of the amplified
product with BstUI (Boehringer, Mannheim, Germany).
